Myocarditis News and Research

RSS

In medicine (cardiology), myocarditis is inflammation of heart muscle (myocardium). It resembles a heart attack but coronary arteries are not blocked.

New Vietnamese enterovirus C4 strains possibly more virulent than B5 strains

A new study published in January 2020 in the journal Scientific Reports reports the presence of a new lineage of enterovirus responsible for the hand-foot-and-mouth disease (HFMD). They think this could be more virulent than the earlier B5 subtype.

12 Apr 2020

What does recovery from COVID-19 look like? It depends. A pulmonologist explains.

Reports of recovery from serious illness caused by the coronavirus have been trickling in from around the world.

9 Apr 2020

Autoimmunity-associated heart dilation linked with heart-failure risk in type 1 diabetes

People with type 1 diabetes, particularly those with poor glycemic control, are at markedly increased risk for cardiovascular disease than the general population.

6 Apr 2020

Mysterious heart damage, not just lung troubles, befalling COVID-19 patients

While the focus of the COVID-19 pandemic has been on respiratory problems and securing enough ventilators, doctors on the front lines are grappling with a new medical mystery.

6 Apr 2020

COVID-19: What the illness looks like

With increasing information about COVID-19 disease gathered first-hand, a more accurate picture of the clinical features is coming together.

2 Apr 2020

COVID-19 and its effects on the cardiovascular system

Researcher have reviewed the evidence showing the effects of the SARS-CoV-2 or novel coronavirus infection (COVID-19) on the cardiovascular system. Their study titled, “Potential Effects of Coronaviruses on the Cardiovascular System: A Review,” was published in the latest issue of JAMA Cardiology.

29 Mar 2020

New scientific statement outlines the resources needed to treat fulminant myocarditis

The resources needed to treat fulminant myocarditis - severe, inflammation of the heart that develops rapidly - are outlined in a new Scientific Statement from the American Heart Association on how best to reduce fatalities from this rare condition.

6 Jan 2020

Stanford-UCSF researchers report new cure for common cold in human cells and mice

Temporarily disabling a single protein inside our cells might be able to protect us from the common cold and other viral diseases, according to a study led by researchers at Stanford University and University of California-San Francisco.

16 Sep 2019

Defective immune signals could underlie some types of fatal heart disease

Researchers have come up with exciting evidence that confirms the role of abnormal immune signaling in myocarditis.

25 Jul 2019

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.

22 Jul 2019

Disruption of immune cell behavior may spur heart disease, heart failure

On an ice hockey team, the players all start off with identical uniforms, skates and a stick. But if you take one of them, add padding, a glove, and a mask; and switch the stick to one with a larger blade, then you get a goalie.

From Johns Hopkins Medicine 19 Jul 2019

Study explores how exposure to potential triggers can increase risk of type 1 diabetes

A new study has investigated how exposure to certain triggers can increase the risk of type 1 diabetes.

22 May 2019

Imaging beyond routine angiography may be helpful in women with suspected MI and no obstructive CAD

A subset of women referred to the cardiac catheterization lab for suspected myocardial infarction thought to be due to a culprit artery are found to have no obstructive coronary artery disease by angiography.

9 May 2019

New study elucidates role of signaling molecule in development of myocarditis

Researchers of Ludwig-Maximilians-Universitaet in Munich have shown that a protein called midkine, a member of the class of signaling molecules known as cytokines, is a key driver of inflammation in the heart muscle that can lead to heart failure in patients with myocarditis.

29 Jan 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Researchers describe key role of enzyme in regulating immune response against Chagas disease parasite

In an article published recently in the journal Nature Communications, researchers affiliated with the University of São Paulo in Brazil describe the central role played by an enzyme called phosphatidylinositol 3-kinase gamma in regulating the immune response against Trypanosoma cruzi, the protozoan parasite that causes Chagas disease.

16 Jul 2018

Myocarditis News and Research

Further Reading

New Vietnamese enterovirus C4 strains possibly more virulent than B5 strains

What does recovery from COVID-19 look like? It depends. A pulmonologist explains.

Autoimmunity-associated heart dilation linked with heart-failure risk in type 1 diabetes

Mysterious heart damage, not just lung troubles, befalling COVID-19 patients

COVID-19: What the illness looks like

COVID-19 and its effects on the cardiovascular system

New scientific statement outlines the resources needed to treat fulminant myocarditis

Stanford-UCSF researchers report new cure for common cold in human cells and mice

Defective immune signals could underlie some types of fatal heart disease

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

Disruption of immune cell behavior may spur heart disease, heart failure

Study explores how exposure to potential triggers can increase risk of type 1 diabetes

Imaging beyond routine angiography may be helpful in women with suspected MI and no obstructive CAD

New study elucidates role of signaling molecule in development of myocarditis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Researchers describe key role of enzyme in regulating immune response against Chagas disease parasite

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News